Frontiers of Medicine

, Volume 13, Issue 1, pp 1–2 | Cite as

Prospects of immunotherapy for cancer

  • Zhinan ChenEmail author


  1. 1.
    June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018; 359 (6382): 1361–1365CrossRefGoogle Scholar
  2. 2.
    Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by antibodies: recent progress. Annu Rev Immunol 2017; 35(1): 285–311CrossRefGoogle Scholar
  3. 3.
    Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med 2017; 68(1): 139–152CrossRefGoogle Scholar
  4. 4.
    Lerner RA. Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol 2016; 16(8): 498–508CrossRefGoogle Scholar
  5. 5.
    Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 2016; 127(26): 3312–3320CrossRefGoogle Scholar
  6. 6.
    Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016; 13(6): 370–383CrossRefGoogle Scholar
  7. 7.
    Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med 2016; 67(1): 165–183CrossRefGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.National Translational Science Center for Molecular MedicineXi’anChina
  2. 2.Department of Cell Biology, School of Basic MedicineFourth Military Medical UniversityXi’anChina

Personalised recommendations